170 related articles for article (PubMed ID: 37283788)
1. Multiparametric Magnetic Resonance Imaging-based Prostate Specific Antigen Density and PI-RADSv2 score help identify Apical Prostate Cancer.
Huang C; Rui R; Feng N; He Q; Gong Y; Li X; He S; Zhou L
J Cancer; 2023; 14(8):1371-1380. PubMed ID: 37283788
[No Abstract] [Full Text] [Related]
2. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
Tosun M; Uslu H
Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
Girometti R; Giannarini G; Panebianco V; Maresca S; Cereser L; De Martino M; Pizzolitto S; Pecoraro M; Ficarra V; Zuiani C; Valotto C
Br J Radiol; 2022 Mar; 95(1131):20210886. PubMed ID: 34762506
[TBL] [Abstract][Full Text] [Related]
4. Determination of Whether Apex or Non-Apex Prostate Cancer Is the Best Candidate for the Use of Prostate-Specific Antigen Density to Predict Pathological Grade Group Upgrading and Upstaging after Radical Prostatectomy.
Huang C; He S; He Q; Gong Y; Song G; Zhou L
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836195
[No Abstract] [Full Text] [Related]
5. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
Woo S; Kim SY; Lee J; Kim SH; Cho JY
Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
[TBL] [Abstract][Full Text] [Related]
6. Preoperative PI-RADS Version 2 scores helps improve accuracy of clinical nomograms for predicting pelvic lymph node metastasis at radical prostatectomy.
Huang C; Song G; Wang H; Lin Z; Wang H; Ji G; Zhang S; Guo Y; Li J; Bao Z; Hong P; Du Y; Li P; He Q; He S; Gong Y; Wang X; Zhou L
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):116-126. PubMed ID: 31383954
[TBL] [Abstract][Full Text] [Related]
7. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
[TBL] [Abstract][Full Text] [Related]
8. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.
Schwen ZR; Mamawala M; Tosoian JJ; Druskin SC; Ross AE; Sokoll LJ; Epstein JI; Carter HB; Gorin MA; Pavlovich CP
BJU Int; 2020 Sep; 126(3):373-378. PubMed ID: 32367635
[TBL] [Abstract][Full Text] [Related]
9. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
[TBL] [Abstract][Full Text] [Related]
10. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
11. Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.
Gaur S; Harmon S; Mehralivand S; Bednarova S; Calio BP; Sugano D; Sidana A; Merino MJ; Pinto PA; Wood BJ; Shih JH; Choyke PL; Turkbey B
J Magn Reson Imaging; 2018 Nov; 48(5):1326-1335. PubMed ID: 29603833
[TBL] [Abstract][Full Text] [Related]
12. 3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard.
Asvadi NH; Afshari Mirak S; Mohammadian Bajgiran A; Khoshnoodi P; Wibulpolprasert P; Margolis D; Sisk A; Reiter RE; Raman SS
Abdom Radiol (NY); 2018 Nov; 43(11):3117-3124. PubMed ID: 29725743
[TBL] [Abstract][Full Text] [Related]
13. Using decision curve analysis to benchmark performance of a magnetic resonance imaging-based deep learning model for prostate cancer risk assessment.
Deniffel D; Abraham N; Namdar K; Dong X; Salinas E; Milot L; Khalvati F; Haider MA
Eur Radiol; 2020 Dec; 30(12):6867-6876. PubMed ID: 32591889
[TBL] [Abstract][Full Text] [Related]
14. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
[TBL] [Abstract][Full Text] [Related]
15. Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score.
Jambor I; Falagario U; Ratnani P; Perez IM; Demir K; Merisaari H; Sobotka S; Haines GK; Martini A; Beksac AT; Lewis S; Pahikkala T; Wiklund P; Nair S; Tewari A
J Magn Reson Imaging; 2020 Apr; 51(4):1075-1085. PubMed ID: 31566845
[TBL] [Abstract][Full Text] [Related]
16. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
[TBL] [Abstract][Full Text] [Related]
17. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
[No Abstract] [Full Text] [Related]
18.
Barnett CL; Davenport MS; Montgomery JS; Kunju LP; Denton BT; Piert M
J Nucl Med; 2019 Dec; 60(12):1705-1712. PubMed ID: 31350321
[TBL] [Abstract][Full Text] [Related]
19. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS.
Park JJ; Park BK
J Magn Reson Imaging; 2017 Jun; 45(6):1753-1759. PubMed ID: 27783436
[TBL] [Abstract][Full Text] [Related]
20. Comparison of multiple abbreviated multiparametric MRI-derived protocols for the detection of clinically significant prostate cancer.
Cereser L; Giannarini G; Bonato F; Pizzolitto S; Como G; Valotto C; Ficarra V; Dal Moro F; Zuiani C; Girometti R
Minerva Urol Nephrol; 2022 Feb; 74(1):29-37. PubMed ID: 33016030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
